# Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

> **NCT05960578** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Apalutamide
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Golimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** PSMA PET Scan
- **PROCEDURE:** Bone Scan

## Key facts

- **NCT ID:** NCT05960578
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2025-07-29
- **Final completion:** 2027-04-14
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960578, "Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05960578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*